Clinical Trials

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05426824 2022-06-22

The Whole-course Management of Pegaspargase in ENKTL

Phase NA Unknown

72 enrolled

Phase EARLY_PHASE1 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT03646422 2022-03-31

AEDV Registry of Primary Cutaneous Lymphoma

Unknown

2,000 enrolled

DermatologicLymphoid

Sezary Syndrome, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell

NCT05208853 2022-01-26

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

9 enrolled

Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02631239 2021-08-25

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Phase 3 Unknown

256 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

37 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04917250 2021-06-08

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

15 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04899414 2021-05-24

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

50 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

264 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04676789 2020-12-21

SPENT

Lymphoma, Extranodal NK-T-Cell

NCT02544425 2020-10-22

VIDL+ASCT

27 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT04490590 2020-07-29

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Phase 4 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT04405375 2020-05-28

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

29 enrolled

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT04337593 2020-04-07

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Lymphoma, Extranodal NK-T-Cell

NCT04096690 2020-03-11

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

22 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Extranodal NK-T-Cell

NCT04008394 2019-08-07

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Phase 1 Unknown

50 enrolled

Hodgkin Disease, Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

61 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03598959 2018-07-26

Tofacitinib Combined With Chidamide in R/R ENKTCL

Lymphoma, Extranodal NK-T-Cell

NCT03154918 2017-11-08

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

60 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03107962 2017-04-11

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT03051542 2017-02-13

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma

Phase NA Unknown

60 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03051555 2017-02-13

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

Phase NA Unknown

60 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02878278 2016-08-25

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

24 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01991158 2016-06-14

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT02080234 2016-04-20

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

40 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01501149 2015-07-17

CTTNKTL-Ⅲ/Ⅳ

Phase 4 Unknown

80 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

18 enrolled

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01933282 2013-12-24

MTN

100 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT01921790 2013-08-22

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT01667302 2013-03-05

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT00725231 2012-05-07

A-CHOP-14

Phase 3 Unknown

274 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT00933673 2012-02-20

New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma

76 enrolled